This document appears to be from a pharmaceutical industry publication discussing regulatory issues. In a few short paragraphs, it touches on recent changes to Schedule H1 and H2 drugs under the Drugs and Cosmetics Act, and how this may impact the pharmaceutical industry in terms of compliance requirements for certain categories of medicines.

1. VOL 1 NO. 1 MAR-APR 2010 www.pharmaleaders.in
21

2. VOL 1 NO. 1 MAR-APR 2010 www.pharmaleaders.in
22